Últimas noticias sobre Verastem (NASDAQ:VSTM) Bolsa

VERASTEM INC

Verastem Oncology

Verastem

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGMH

ANTE

ARBE

ARLO

ATXI

Bakkt Holdings, Inc. Class A Common Stock

BKKT

FINV

GNPX

GRAB

HNRG

HROW

HYPR

KTCC

VRPX

VSTM

Las acciones de Harrow subieron un 23,1% en el premercado. Descubre qué otras compañías están ganando y perdiendo antes de la apertura.

Las acciones de Harrow (HROW) se disparan un 23%; aquí están 20 acciones que se mueven en el premercado

Verastem Inc

Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, for the first-line treatment of patients with KRAS G12D-mutated locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) and for the treatment of patients with KRAS G12D-mutated locally advanced or metastatic PDAC who have received at least one prior line of standard systemic therapy. Fast Track is a process designed to facilitate the development and expedite the review of new drugs intended to treat or prevent serious conditions and address unmet medical needs.

Government

Regulations

Verastem Gets FDA Boost for New Oral Treatment Targeting Aggressive Pancreatic Tumors

Robust objective response rates were observed (31% overall, 44% in KRAS-mutant, and 17% in KRAS wild-type) in patients whose cancer had progressed after multiple prior lines of therapy
The majority of patients (82%) had some reduction in target lesions, regardless of KRAS mutation status
Median progression-free survival was 12.9 months overall, 31.0 months in KRAS-mutant, and 12.8 months in KRAS wild-type
Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fascopubs.org%2Fdoi%2F10.1200%2FJCO-25-00112&amp;esheet=54289407&amp;newsitemid=20250711844835&amp;lan=en-US&amp;anchor=online&amp;index=1&amp;md5=dd635fb35cc9bae70452c67156766165">online</a> in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate (ORR) of 31% in all patients with recurrent low-grade serous ovarian cancer (LGSOC). The full manuscript, titled "Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201," will also appear in the print publication of JCO.

Biotech

General

Verastem's Ovarian Cancer Trial Results Published In Journal Of Clinical Oncology, Titled "Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer"; Verastem's Avutometinib Combo Shows 31% Overall Response Rate In Ovarian Cancer Trial

FRAME study demonstrated a 42.3% ORR and 20.1 months median PFS for all patients with low-grade serous ovarian cancer (LGSOC), regardless of KRAS mutation; for patients with KRAS-mutated LGSOC, ORR and mPFS were 58.3% and 30.8 months, respectively
Study conducted by the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust demonstrated the importance of the intermittent dosing schedule of the combination of avutometinib and defactinib to improve tolerability and anti-tumor activity
Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that updated results from the Phase 1/2 FRAME study conducted by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were published <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-025-03763-y&amp;esheet=54284274&amp;newsitemid=20250630352590&amp;lan=en-US&amp;anchor=online&amp;index=1&amp;md5=c8c6436bdaf119a55fb28a2d754f2661">online</a> in Nature Medicine. The full manuscript, titled "Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial," was the first-in-human study to evaluate the safety, tolerability, and efficacy of avutometinib in combination with defactinib in patients with low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), and other solid tumor types.

Verastem Oncology Announces Publication Of Updated Results From Phase 1/2 FRAME Study Conducted By The Institute Of Cancer Research, London, And The Royal Marsden NHS Foundation Trust, In Nature Medicine

RBC Capital analyst Leonid Timashev maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Outperform and lowers the price target from $16 to $12.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $12

Verastem Oncology Doses First Patient With VS-7375 In Phase 1/2a Trial

<h3>Gainers</h3>
<ul>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) stock rose 376.8% to $23.5 during Monday's regular session. The market value of their outstanding shares is at $31.1 million. </li>
<li>Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) stock increased by 64.08% to $31.09. The company's market cap stands at $1.9 billion. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock rose 59.82% to $1.79. The company's market cap stands at $25.6 million. </li>
<li>Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) shares rose 58.0% to $0.95. The company's market cap stands at $74.1 million. </li>
<li>Processa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock moved upwards by 56.58% to $0.46. The company's market cap stands at $5.4 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 40.92% to $0.4. The company's market cap stands at $2.3 million. The company's, Q1 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock declined by 31.2% to $0.74 during Monday's regular session. The company's market cap stands at $38.1 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock declined by 27.47% to $4.41. The company's market cap stands at $82.8 million. </li>
<li>BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) shares fell 19.24% to $4.24. The market value of their outstanding shares is at $15.7 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares decreased by 18.82% to $6.11. The company's market cap stands at $335.4 million. </li>
<li>TherapeuticsMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXMD#NASDAQ">TXMD</a>) stock declined by 17.81% to $1.2. The market value of their outstanding shares is at $13.8 million. </li>
<li>Olema Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) stock fell 16.1% to $4.43. The market value of their outstanding shares is at $303.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLRX

BMGL

LYRA

MODV

OLMA

PCSA

PSTV

TXMD

VERA

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Monday.
The Dow traded down 0.49% to 42,064.07 while the NASDAQ rose 0.21% to 19,154.77. The S&amp;P 500 also fell, dropping, 0.11% to 5,905.30.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a>
Leading and Lagging Sectors Energy shares jumped by 0.6% on Monday.
In trading on Monday, real estate stocks fell by 1.5%.
Top Headline
The ISM manufacturing PMI declined to 48.5 in May compared to 48.7 in April, also missing market estimates of 49.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares shot up 486% to $28.90 after the company announced its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.</li>
<li>Shares of Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) got a boost, surging 64% to $31.12 after the company released ORIGIN Phase 3 trial data.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares were also up, gaining 51% to $10.34 after the company announced a 250MW AI data center lease with CoreWeave.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Verastem, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) shares dropped 20% to $6.01. The company provided updated data for the dose escalation part of its Phase 1/2 trial of GFH375.</li>
<li>Shares of SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) were down 37% to $48.35 after the company announced a mixed-shelf offering</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) was down, falling 32% to $0.73 after the company announced it commenced a public offering of pre-funded warrants.</li>
</ul>
Commodities In commodity news, oil traded up 3.3% to $62.82 while gold traded up 2.6% at $3,400.70.
Silver traded up 4.7% to $34.595 on Monday, while copper rose 3.6% to $4.8470.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 declined 0.14%, while Spain's IBEX 35 Index rose 0.36%. London's FTSE 100 rose 0.02%, Germany's DAX 40 fell 0.28% and France's CAC 40 fell 0.19% during the session.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei falling 1.30%, Hong Kong's Hang Seng Index dipping 0.57% and India's BSE Sensex declining 0.1%.
Economics
<ul class="wp-block-list">
<li>The ISM Manufacturing PMI declined to 48.5 in May compared to 48.7 in April, also missing market estimates of 49.5.</li>
<li>U.S. construction spending declined by 0.4% month-over-month to an annual rate of $2,152.4 billion in April following a revised 0.8% fall in March.</li>
<li>The S&amp;P Global manufacturing PMI was revised lower to a reading of 52 in May versus a preliminary reading of 52.3.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719355/top-3-utilities-stocks-that-may-crash-in-june">Top 3 Utilities Stocks That May Crash In June</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

APLD

SBET

Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May

Verastem Oncology&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) released on Monday updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">VS-7375 in the U.S.)</a>.
As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall response rate (ORR) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45721800/verastem-oncology-announces-updated-data-from-partner-genfleet-therapeutics-phase-1-study-in-china" rel="noreferrer noopener">of 52% and 42%, respectively</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45297255/fda-grants-accelerated-approval-to-verastems-combination-drug-for-ovarian-cancer" rel="noreferrer noopener">FDA Grants Accelerated Approval To Verastem&#8217;s Combination Drug For Ovarian Cancer</a>
Verastem&#8217;s partner, GenFleet Therapeutics, presented the updated data at the 2025 American Society of Clinical Oncology Annual Meeting.
ASCO 2025 Presentation Highlights
<ul class="wp-block-list">
<li>GenFleet reported that 62 patients were enrolled in the Phase 1 portion of the study in China, receiving oral doses ranging from 100 to 900 mg daily.</li>
<li>As of the data cutoff of May 16, 2025, 23 efficacy-evaluable patients with PDAC and 12 efficacy-evaluable patients with NSCLC, who received daily dosages of 400 or 600 mg and had at least one post-treatment tumor assessment, achieved an ORR of 52% and a disease control rate (DCR) of 100%, and an ORR of 42% and a DCR of 83%, respectively.</li>
</ul>
As of the cutoff date of March 31, 2025, GenFleet reported that no dose-limiting toxicities (DLTs) were observed across all dose levels (100-900 mg QD), and the treatment-related adverse events (TRAEs) were mostly Grade 1/2.
VSTM Price Action: Verastem Oncology stock is trading 18.62% lower at $6.12 at publication on Monday.
<h1 class="wp-block-heading">Looking At Trends: Verastem Oncology</h1>
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Verastem, an investor could make an assessment about a stock's long-term prospects using a moving average and trend line. 
If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Verastem, the 200-day moving average sits at $4.96, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is below the current price of $6.13. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/45724879/cactus-takes-majority-stake-in-baker-hughes-spc-for-global-reach" target="_blank" rel="noreferrer noopener">Cactus Takes Majority Stake In Baker Hughes&#8217; SPC For Global Reach</a></li>
</ul>
Photo: Shutterstock

Health Care

What's Going On With Verastem Oncology Stock On Monday?

WIIM

Verastem shares are trading lower. The company provided updated data for the dose escalation part of its Phase 1/2 trial of GFH375.

In the study in China, GFH375 demonstrated an ORR of 52% in patients with pancreatic ductal adenocarcinoma and an ORR of 42% with non-small cell lung cancer
Company activating sites in the U.S. for VS-7375 to begin enrollment in the Phase 1/2a trial
Company will host an R&amp;D investor webcast on Monday, June 2, at 11:00 am CDT to review updated RAMP 205 data as well as updated data on GFH375 presented at the ASCO 2025 Annual Meeting
Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall response rate (ORR) of 52% and 42%, respectively. The updated data were presented by Verastem's partner, GenFleet Therapeutics, in a rapid oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025, in Chicago, IL.

Verastem Oncology Announces Updated Data From Dose Escalation Phase Of The Phase 1/2 Trial Of GFH375; Study Shows ORR Of 52% In Patients With Pancreatic Ductal Adenocarcinoma And ORR Of 42% With Non-Small Cell Lung Cancer

Verastem Oncology shares are trading higher after the company announced phase 2 dose level 1 shows 83% overall response rate in frontline metastatic pancreatic ductal adenocarcinoma.

Selected recommended Phase 2 dose: Dose level 1 demonstrated an ORR of 83% (10/12) in frontline metastatic pancreatic ductal adenocarcinoma
Plans for registrational Phase 3 study underway in frontline metastatic pancreatic ductal adenocarcinoma
Company will host an R&amp;D investor webcast on Monday, June 2 at 11:00 am CDT to review the updated RAMP 205 data as well as updated data on VS-7375 presented at ASCO
Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the front-line for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). As of April 25, 2025, patients in the dose level 1 cohort, which was selected as the recommended Phase 2 dose (RP2D), achieved an overall response rate (ORR) of 83% (10/12).
The Company will host a research and development (R&amp;D) investor webcast on Monday, June 2 at 11:00 am CDT to review the full updated data from RAMP 205 and the updated data from the Phase 1/2 study in China of VS-7375 (also known as GFH375), an oral KRAS G12D (ON/OFF) inhibitor, by partner GenFleet Therapeutics that will be presented in a rapid oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL on June 2, 2025.

Verastem Oncology's Phase 2 Dose Level 1 Shows 83% Overall Response Rate In Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Verastem Reveals Updated Results From RAMP 205 Evaluating Avutometinib Plus Defactinib In Combination With Standard-Of-Care Chemotherapy In Frontline Metastatic Pancreatic Ductal Adenocarcinoma

Tempus AI Collaborates With Verastem Oncology To Develop Companion Diagnostic Test Using FDA-Approved xT CDx Assay For KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.71) by 11.27 percent. This is a 19.39 percent increase over losses of $(0.98) per share from the same period last year.

Earnings

Earnings Misses

Verastem Q1 Adj. EPS $(0.79) Misses $(0.71) Estimate

HC Wainwright &amp; Co. analyst Sean Lee maintains Verastem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) with a Buy and raises the price target from $10 to $14.

HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $14

The Food and Drug Administration on Thursday granted accelerated approval to Verastem Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>) Avmapki Fakzynja Co-pack, a combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">received prior systemic therapy</a>.
Efficacy was evaluated in RAMP-201 (NCT04625270), an open-label, multicenter trial that included 57 adult patients with measurable KRAS-mutated recurrent LGSOC.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42743560/why-is-cancer-focused-verastem-oncology-stock-trading-higher-on-tuesday" rel="noreferrer noopener">Why Is Cancer-Focused Verastem Oncology Stock Trading Higher On Tuesday?</a>
Patients <a target="_blank" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low" rel="noreferrer noopener">received</a> avutometinib 3.2 mg orally twice weekly (Day 1 and Day 4) and defactinib 200 mg orally twice daily, both taken for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.
The major efficacy outcome measure was overall response rate (ORR). An additional efficacy outcome measure was duration of response (DOR).
The confirmed ORR was 44%, and the DOR range was 3.3 to 31.1 months.
The recommended avutometinib dose is 3.2 mg (four 0.8 mg capsules) taken orally twice weekly (Day 1 and Day 4) for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.
The recommended defactinib dose is 200 mg (one tablet) taken orally twice daily for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.
In April, Verastem Oncology&nbsp;announced a private placement of approximately $24 million of shares at $7.00 per share and, in lieu of common stock, $51 million of pre-funded warrants at $6.9999 per pre-funded warrant.
Verastem expects to receive gross proceeds from the offering of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45007065/verastem-oncology-announces-75-million-private-placement" rel="noreferrer noopener">approximately $75 million</a>.
The company said it would use the proceeds to fund the potential launch of avutometinib and defactinib, as well as continued clinical research and development of product candidates, including VS-7375, working capital, and other general corporate purposes.
In April, the FDA cleared Verastem Oncology&#8217;s Investigational New Drug application of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor for clinical evaluation.
The company expects to initiate a Phase 1/2a study in mid-2025 and plans for multiple expansion cohorts, including combinations, in advanced solid tumors, such as pancreatic, colorectal, and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44964117/verastem-oncology-announces-u-s-ind-clearance-of-vs-7375-oral-kras-g12d-onoff-inhibitor-enabling-p" rel="noreferrer noopener">non-small cell lung cancer</a>.
Price Action: VSTM stock was trading 3.14% higher at $6.89 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/04/45059756/trump-era-fda-appointees-request-new-trials-for-novavax-covid-vaccine-reportedly-delaying-approval-timeline" target="_blank" rel="noreferrer noopener">Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer

Verastem Shares Resume Trade

Trading Halt: Halt status updated at 1:40:00 PM ET: Quotation Resumption: News and Resumption Times

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low</a>

'FDA Grants Accelerated Approval To The Combination Of Avutometinib And Defactinib For KRAS-Mutated Recurrent Low-grade Serous Ovarian Cancer'

Press Releases

Verastem Oncology to Present at the Jefferies Global Healthcare Conference

Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors

Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology

Small Cap

Opinion

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer

Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Comments

Verastem

Noticias

Últimas noticias sobre Verastem (NASDAQ:VSTM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL